Krishnamurthy Ramya, Pallavee P, Ghose Seetesh
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College & Research Institute, Pondicherry, India.
J Family Reprod Health. 2015 Jun;9(2):75-81.
To evaluate the safety and efficacy of Isosorbide mononitrate (IMN) as a cervical ripening agent prior to induction of labour in term pregnant women.
A randomized placebo-controlled study was conducted on 100 term singleton pregnancies planned for induction of labour. The participants were randomly assigned to two groups. One group received 40 mg IMN and the other group received 40mg of placebo kept vaginally. The main outcome of this study was to evaluate the efficacy of IMN in cervical ripening based on the change in modified Bishop score and the effect on time duration between the drug insertion and delivery. Safety of isosorbide mononitrate was assessed by measuring variables related to maternal and neonatal outcomes.
Baseline demographic characteristics were similar in both groups. The mean change in modified Bishop score after 2 doses of 40mg IMN was insignificant when compared to placebo. Though IMN shortened the time duration between the drug insertion to delivery when compared to placebo, it was statistically insignificant. The need for oxytocin and 2(nd) ripening agent was less in IMN group when compared to placebo group but statistically this also proved to be insignificant. It was noted that there was an increase in caesarean deliveries in IMN than in placebo group. IMN did not cause any significant change in maternal hemodynamics and adverse side effects. Though NICU admission and stay was less in IMN than in placebo group, it was statistically insignificant.
Though IMN did not cause any maternal and neonatal adverse effects, it was found to be inefficient in comparison to placebo as a cervical ripening agent.
评估单硝酸异山梨酯(IMN)作为足月孕妇引产术前宫颈成熟剂的安全性和有效性。
对100例计划引产的足月单胎妊娠进行了一项随机安慰剂对照研究。参与者被随机分为两组。一组接受40mg IMN,另一组接受阴道放置的40mg安慰剂。本研究的主要结果是根据改良Bishop评分的变化评估IMN在宫颈成熟方面的有效性,以及对药物放置至分娩的时间间隔的影响。通过测量与孕产妇和新生儿结局相关的变量来评估单硝酸异山梨酯的安全性。
两组的基线人口统计学特征相似。与安慰剂相比,2剂40mg IMN后改良Bishop评分的平均变化不显著。尽管与安慰剂相比,IMN缩短了药物放置至分娩的时间间隔,但在统计学上不显著。与安慰剂组相比,IMN组对催产素和第二剂宫颈成熟剂的需求较少,但在统计学上这也不显著。值得注意的是,IMN组剖宫产的发生率高于安慰剂组。IMN对孕产妇血流动力学和不良副作用没有引起任何显著变化。尽管IMN组新生儿重症监护病房(NICU)的入住率和住院时间低于安慰剂组,但在统计学上不显著。
尽管IMN没有引起任何孕产妇和新生儿不良反应,但作为宫颈成熟剂,与安慰剂相比,它被发现是无效的。